Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 47 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/18/2007 First Published: 2/1/2002


1.		Phase IV Randomized Study of Filgrastim (G-CSF) or Pegfilgrastim as Secondary Prophylaxis Versus Conservative Management of Chemotherapy-Induced Neutropenia for Maintenance of Chemotherapy in Women With Early Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care				Closed				18 and over				Other				ACCOG-SCTN-BR0101 SCTN-BR0101, EU-20143, NCT00030758

Last Modified: 5/9/2007 First Published: 5/1/2000


2.		Phase III Pilot Randomized Study of Filgrastim-SD/01 Versus Filgrastim (G-CSF) With Concurrent Chemotherapy in Patients With Newly Diagnosed Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				25 and under at diagnosis				NCI				NCI-00-C-0092G AMGEN-20000124, NCT00020137

Last Modified: 11/29/2007 First Published: 7/1/2000


3.		Phase III Randomized Adjuvant Study of Tumor Volume-Directed Pelvic Radiotherapy With or Without Paraaortic Radiotherapy Followed By Cisplatin and Doxorubicin With or Without Paclitaxel in Patients With Stage III Endometrial Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				NCI				GOG-0184 ECOG-G0184, RTOG-EN0130, NCT00006011, GOG-0184

Last Modified: 5/29/2008 First Published: 10/25/2003


4.		Phase III Randomized Study of Paclitaxel, Ifosfamide, and Cisplatin Versus Vinblastine, Ifosfamide, and Cisplatin as Second-Line Therapy in Men With Progressive or Recurrent Metastatic Germ Cell Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				CALGB-90106 CALGB-90106, NCT00072215

Last Modified: 12/18/2006 First Published: 5/23/2005


5.		Phase III Randomized Study of Neoadjuvant Cisplatin and Docetaxel With Versus Without Thoracic Conformal Radiotherapy Followed By Surgical Resection and Docetaxel in Patients With Newly Diagnosed Favorable Prognosis Stage IIIA Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				RTOG-0412 SWOG-S0332, RTOG-0412-SWOG-S0332, CALGB-RTOG-0412, ECOG-RTOG-0412, NCCTG-RTOG-0412, NCT00113386

Last Modified: 5/7/2007 First Published: 1/28/2007


6.		Phase III Randomized Study of Adjuvant Therapy Comprising Epirubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With Versus Without Fluorouracil and/or Pegfilgrastim in Women With Node-Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 70				Other				GIM-2 EU-20681, NCT00433420

Last Modified: 7/7/2008 First Published: 6/23/2003


7.		Phase II Study of Oblimersen in Combination With Doxorubicin and Docetaxel in Patients With Metastatic or Locally Advanced Breast Cancer (Phase I portion of the study completed as of 8/16/04)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				MDA-DM-02700 NCI-6023, NCT00063934, 6023

Last Modified: 5/24/2008 First Published: 1/23/2004


8.		Phase II Study of Induction Chemotherapy Comprising Doxorubicin and Cisplatin Followed By Combretastatin A4 Phosphate and Radiotherapy in Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer (Phase I portion of the study closed as of 5/6/04)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				CASE-CWRU-3302 CWRU-040337, OXIGENE-CWRU-3302, NCT00077103, CASE-3302

Last Modified: 1/2/2008 First Published: 6/23/2004


9.		Phase I/II Study of Oblimersen in Combination With Rituximab, Ifosfamide, Carboplatin, and Etoposide in Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				UCCRC-12975A 6243, NCI-6243, NCT00086944

Last Modified: 8/2/2006 First Published: 9/16/2005


10.		Phase I/II Study of Erlotinib in Combination With Docetaxel and Carboplatin as Front-Line Therapy Followed by Maintenance Therapy With Erlotinib in Patients With Newly Diagnosed Stage III or IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				PSOC-2001 AVENTIS-PSOC-2001, PSOC-IRB-5689, NCT00217529

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute